None of the 29 investors followed here reported a position in EVMN in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a EVMN trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Jul 7, 2026 | Carver KyleChief Financial Officer | Purchase at price 13.26 per share. | 1K | $13.26K |
| Jul 6, 2026 | Kirsch Arthur SDirector | Purchase at price 13.30 per share. | 10K | $133.00K |
| Jun 21, 2026 | Pena Luis CChief Executive Officer | Sale at price 22.71 per share. | 7.4K | $168.92K |
| Jun 21, 2026 | Drew Janice SuzannOfficer | Sale at price 22.63 per share. | 20K | $452.60K |
| Jun 21, 2026 | Patel Jeegar Pravinkumar Ph.D.Officer | Sale at price 22.50 per share. | 1.5K | $33.48K |
| Jun 21, 2026 | Drew Janice SuzannOfficer | Conversion of Exercise of derivative security at price 2.99 - 3.84 per share. | 20K | $63.06K |
| Jun 21, 2026 | Patel Jeegar Pravinkumar Ph.D.Officer | Conversion of Exercise of derivative security at price 3.84 per share. | 1.5K | $5.71K |
| Jun 1, 2026 | Cohen David EDirector | Sale at price 20.21 - 21.38 per share. | 6.1K | $123.09K |
| May 31, 2026 | Pena Luis CChief Executive Officer | Sale at price 22.74 per share. | 16.8K | $381.74K |
| May 31, 2026 | Patel Jeegar Pravinkumar Ph.D.Officer | Sale at price 22.74 per share. | 16.7K | $379.46K |
| May 31, 2026 | Patel Jeegar Pravinkumar Ph.D.Officer | Conversion of Exercise of derivative security at price 3.84 per share. | 13.5K | $51.89K |
| May 27, 2026 | Carver KyleChief Financial Officer | Sale at price 22.84 per share. | 18.2K | $415.12K |
| May 27, 2026 | Moss Gregory S. Esq.Officer | Sale at price 22.83 per share. | 14.2K | $324.71K |
| May 27, 2026 | Carver KyleChief Financial Officer | Conversion of Exercise of derivative security at price 2.99 per share. | 15K | $44.85K |
| May 27, 2026 | Moss Gregory S. Esq.Officer | Conversion of Exercise of derivative security at price 1.71 per share. | 14.2K | $24.32K |
| Feb 16, 2026 | Ra Capital Management, L.P.Director | Stock Award(Grant) at price 27.88 per share. | 35.9K | $1.00M |
| Feb 16, 2026 | Weegen Felice Verduyn-VanDirector and Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) at price 27.88 per share. | 358.7K | $10.00M |
| Feb 16, 2026 | Lsp 7 Cooperative UaBeneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) at price 27.88 per share. | 358.7K | $10.00M |
| Dec 18, 2025 | Hopfner Robert LorneDirector and Beneficial Owner of more than 10% of a Class of Security | Purchase at price 17.35 per share. | 1K | $17.35K |
| Nov 6, 2025 | Ra Capital Management, L.P.Beneficial Owner of more than 10% of a Class of Security | Purchase at price 16.00 per share. | 1.25M | $20.00M |
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is headquartered in Palo Alto, California.
Buy / hold / sell counts